LH和FSH在多囊卵巢综合征中的作用
The Role of LH and FSH in Polycystic Ovary Syndrome
摘要: 多囊卵巢综合征(PCOS)是一种由于糖代谢异常与内分泌失调引发的以高雄激素血症、稀发排卵或无排卵、胰岛素抵抗、超重或肥胖、月经不规则等为特征的一种生殖内分泌性疾病，是困扰育龄期女性难孕难育、不孕不育的重要原因之一。在PCOS中，下丘脑–垂体–卵巢轴功能障碍是造成多种不同临床表现及卵巢功能和结构改变的主要原因。卵泡刺激素和黄体生成素是重要的垂体促性腺激素。在PCOS疾病的发生和发展过程中，黄体生成素增多、卵泡刺激素降低、黄体生成素/卵泡刺激素比值升高，对于该病的诊断有重要的提示意义，同时对于PCOS治疗后的临床预后有着一定的预测意义。
Abstract: Polycystic ovary syndrome (PCOS) is a reproductive endocrine disease caused by abnormal glucose metabolism and endocrine disorders, which is characterized by hyperandrogenism, rare ovulation or anovulation, insulin resistance, overweight or obesity, irregular menstruation, etc. It is one of the important reasons that plague women of childbearing age who are difficult to conceive, have children and have infertility. In PCOS, dysfunction of the hypothalamic-pituitary-ovarian axis is the main cause of various clinical manifestations and changes in ovarian function and structure. Follicle stimulating hormone and luteinizing hormone are important pituitary gonadotropins. During the occurrence and development of PCOS, the increase of luteinizing hormone, the decrease of FSH, and the increase of the ratio of luteinizing hormone to FSH pose important suggestive significance for the diagnosis of PCOS, and also represent certain predictive significance for the clinical prognosis after treatment of PCOS.
文章引用：杨舒婷, 刘东方. LH和FSH在多囊卵巢综合征中的作用[J]. 临床医学进展, 2025, 15(4): 711-717. https://doi.org/10.12677/acm.2025.154986

参考文献

[1] Yang, J. and Chen, C. (2024) Hormonal Changes in PCOS. Journal of Endocrinology, 261, e230342. [Google Scholar] [CrossRef] [PubMed]
[2] Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L. and Azziz, R. (2016) Criteria, Prevalence, and Phenotypes of Polycystic Ovary Syndrome. Fertility and Sterility, 106, 6-15. [Google Scholar] [CrossRef] [PubMed]
[3] Moran, L.J., Stepto, N.K., Brennan, L., Garad, R., Misso, M., Norman, R., et al. (2019) International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome-Lifestyle Management and Models of Care Guideline Development Group. Obesity Research & Clinical Practice, 13, 323. [Google Scholar] [CrossRef] 
[4] 多囊卵巢综合征诊治路径共识专家组. 多囊卵巢综合征诊治路径专家共识[J]. 中华生殖与避孕杂志, 2023, 43(4): 337-345.
[5] Zhao, H., Zhang, Y., Ye, J., Wei, H., Huang, Z., Ning, X., et al. (2021) A Comparative Study on Insulin Secretion, Insulin Resistance and Thyroid Function in Patients with Polycystic Ovary Syndrome with and without Hashimoto’s Thyroiditis. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 14, 1817-1821. [Google Scholar] [CrossRef] [PubMed]
[6] El Hayek, S., Bitar, L., Hamdar, L.H., Mirza, F.G. and Daoud, G. (2016) Poly Cystic Ovarian Syndrome: An Updated Overview. Frontiers in Physiology, 7, Article 124. [Google Scholar] [CrossRef] [PubMed]
[7] Goodarzi, M.O., Dumesic, D.A., Chazenbalk, G. and Azziz, R. (2011) Polycystic Ovary Syndrome: Etiology, Pathogenesis and Diagnosis. Nature Reviews Endocrinology, 7, 219-231. [Google Scholar] [CrossRef] [PubMed]
[8] Emanuel, R.H.K., Roberts, J., Docherty, P.D., Lunt, H., Campbell, R.E. and Möller, K. (2022) A Review of the Hormones Involved in the Endocrine Dysfunctions of Polycystic Ovary Syndrome and Their Interactions. Frontiers in Endocrinology, 13, Article 1017468. [Google Scholar] [CrossRef] [PubMed]
[9] Yang, H., Di, J., Pan, J., Yu, R., Teng, Y., Cai, Z., et al. (2020) The Association between Prolactin and Metabolic Parameters in PCOS Women: A Retrospective Analysis. Frontiers in Endocrinology, 11, Article 263. [Google Scholar] [CrossRef] [PubMed]
[10] Ruddenklau, A. and Campbell, R.E. (2019) Neuroendocrine Impairments of Polycystic Ovary Syndrome. Endocrinology, 160, 2230-2242. [Google Scholar] [CrossRef] [PubMed]
[11] McCartney, C.R. and Marshall, J.C. (2016) Polycystic Ovary Syndrome. New England Journal of Medicine, 375, 54-64. [Google Scholar] [CrossRef] [PubMed]
[12] Ulloa-Aguirre, A., Dias, J.A., Huhtaniemi, I., et al. (2017) Endocrinology of the Testis and Male Reproduction. Springer, 1-52.
[13] Conforti, A., Di Girolamo, R., Guida, M., Alviggi, C. and Casarini, L. (2025) Pharmacogenomic of LH and Its Receptor: Are We Ready for Clinical Practice? Reproductive Biology and Endocrinology, 23, Article No. 29. [Google Scholar] [CrossRef] [PubMed]
[14] Witchel, S.F., Teede, H.J. and Peña, A.S. (2019) Curtailing PCOS. Pediatric Research, 87, 353-361. [Google Scholar] [CrossRef] [PubMed]
[15] Bosch, E., Alviggi, C., Lispi, M., Conforti, A., Hanyaloglu, A.C., Chuderland, D., et al. (2021) Reduced FSH and LH Action: Implications for Medically Assisted Reproduction. Human Reproduction, 36, 1469-1480. [Google Scholar] [CrossRef] [PubMed]
[16] Mikhael, S., Punjala-Patel, A. and Gavrilova-Jordan, L. (2019) Hypothalamic-Pituitary-Ovarian Axis Disorders Impacting Female Fertility. Biomedicines, 7, Article 5. [Google Scholar] [CrossRef] [PubMed]
[17] Baculescu, N. (2013) The Role of Androgen Receptor Activity Mediated by the CAG Repeat Polymorphism in the Pathogenesis of PCOS. Journal of Medicine and Life, 6, 18-25.
[18] Coutinho, E.A. and Kauffman, A.S. (2019) The Role of the Brain in the Pathogenesis and Physiology of Polycystic Ovary Syndrome (PCOS). Medical Sciences, 7, Article 84. [Google Scholar] [CrossRef] [PubMed]
[19] Blank, S., McCartney, C., Helm, K. and Marshall, J. (2007) Neuroendocrine Effects of Androgens in Adult Polycystic Ovary Syndrome and Female Puberty. Seminars in Reproductive Medicine, 25, 352-359. [Google Scholar] [CrossRef] [PubMed]
[20] Pellatt, L., Rice, S. and Mason, H.D. (2010) Anti-müLlerian Hormone and Polycystic Ovary Syndrome: A Mountain Too High? Reproduction, 139, 825-833. [Google Scholar] [CrossRef] [PubMed]
[21] Durlinger, A.L.L. (2002) Anti-mullerian Hormone Inhibits Initiation of Primordial Follicle Growth in the Mouse Ovary. Endocrinology, 143, 1076-1084. [Google Scholar] [CrossRef] [PubMed]
[22] Homburg, R. and Crawford, G. (2014) The Role of AMH in Anovulation Associated with PCOS: A Hypothesis. Human Reproduction, 29, 1117-1121. [Google Scholar] [CrossRef] [PubMed]
[23] Dewailly, D., Robin, G., Peigne, M., Decanter, C., Pigny, P. and Catteau-Jonard, S. (2016) Interactions between Androgens, FSH, Anti-Müllerian Hormone and Estradiol during Folliculogenesis in the Human Normal and Polycystic Ovary. Human Reproduction Update, 22, 709-724. [Google Scholar] [CrossRef] [PubMed]
[24] Pellatt, L., Rice, S., Dilaver, N., Heshri, A., Galea, R., Brincat, M., et al. (2011) Anti-müLlerian Hormone Reduces Follicle Sensitivity to Follicle-Stimulating Hormone in Human Granulosa Cells. Fertility and Sterility, 96, 1246-1251.e1. [Google Scholar] [CrossRef] [PubMed]
[25] Cimino, I., Casoni, F., Liu, X., Messina, A., Parkash, J., Jamin, S.P., et al. (2016) Novel Role for Anti-Müllerian Hormone in the Regulation of GNRH Neuron Excitability and Hormone Secretion. Nature Communications, 7, Article No. 10055. [Google Scholar] [CrossRef] [PubMed]
[26] Andersen, C.Y. and Byskov, A.G. (2006) Estradiol and Regulation of Anti-Müllerian Hormone, Inhibin-A, and Inhibin-B Secretion: Analysis of Small Antral and Preovulatory Human Follicles’ Fluid. The Journal of Clinical Endocrinology & Metabolism, 91, 4064-4069. [Google Scholar] [CrossRef] [PubMed]
[27] Laven, J.S.E. (2019) Follicle Stimulating Hormone Receptor (FSHR) Polymorphisms and Polycystic Ovary Syndrome (PCOS). Frontiers in Endocrinology, 10, Article 23. [Google Scholar] [CrossRef] [PubMed]
[28] Zhao, L., Zhu, C., Chen, Y., Chen, C., Cheng, J., Xia, F., et al. (2018) LH/FSH Ratio Is Associated with Visceral Adipose Dysfunction in Chinese Women Older than 55. Frontiers in Endocrinology, 9, Article 419. [Google Scholar] [CrossRef] [PubMed]
[29] Su, N., Huang, C., Liu, J., Kang, D., Wang, S., Liao, L., et al. (2021) Association between Baseline LH/FSH and Live-Birth Rate after Fresh-Embryo Transfer in Polycystic Ovary Syndrome Women. Scientific Reports, 11, Article No. 20490. [Google Scholar] [CrossRef] [PubMed]
[30] Banaszewska, B., Spaczyński, R.Z., Pelesz, M., et al. (1995) Incidence of Elevated LH/FSH Ratio in Polycystic Ovary Syndrome Women with Normo-and Hyperinsulinemia. Roczniki Akademii Medycznej w Bialymstoku, 48, 131-134.
[31] Barman, B., Nath, C., Das, A., Rajkhowa, P., Baruah, P., Baruah, M., et al. (2019) Prolactin and Thyroid Stimulating Hormone Affecting the Pattern of LH/FSH Secretion in Patients with Polycystic Ovary Syndrome: A Hospital-Based Study from North East India. Journal of Family Medicine and Primary Care, 8, 256-260. [Google Scholar] [CrossRef] [PubMed]
[32] Le, M.T., Le, V.N.S., Le, D.D., Nguyen, V.Q.H., Chen, C. and Cao, N.T. (2019) Exploration of the Role of Anti‐Mullerian Hormone and LH/FSH Ratio in Diagnosis of Polycystic Ovary Syndrome. Clinical Endocrinology, 90, 579-585. [Google Scholar] [CrossRef] [PubMed]
[33] Yue, C., Lu, L., Li, M., Zhang, Q. and Ying, C. (2018) Threshold Value of Anti-Mullerian Hormone for the Diagnosis of Polycystic Ovary Syndrome in Chinese Women. PLOS ONE, 13, e0203129. [Google Scholar] [CrossRef] [PubMed]
[34] Malini, N.A. and Roy George, K. (2018) Evaluation of Different Ranges of LH:FSH Ratios in Polycystic Ovarian Syndrome (PCOS)—Clinical Based Case Control Study. General and Comparative Endocrinology, 260, 51-57. [Google Scholar] [CrossRef] [PubMed]
[35] Llata, E.S.D.L., Moraga-Sánchez, M.R., Romeu-Sarrió, A., et al. (2016) [LH-FSH ratio and Polycystic Ovary Syndrome: A Forgotten Test? Ginecología Y Obstetricia de México, 84, 84-94.
[36] Cho, L.W., Jayagopal, V., Kilpatrick, E.S., Holding, S. and Atkin, S.L. (2006) The LH/FSH Ratio Has Little Use in Diagnosing Polycystic Ovarian Syndrome. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 43, 217-219. [Google Scholar] [CrossRef] [PubMed]
[37] Wiser, A., Shehata, F., Holzer, H., et al. (2013) Effect of High LH/FSH Ratio on Women with Polycystic Ovary Syndrome Undergoing in Vitro Maturation Treatment. Journal of Reproductive Medicine, 58, 219-223.
[38] Woo, I., Tobler, K., Khafagy, A., et al. (2015) Predictive Value of Elevated LH/FSH Ratio for Ovulation Induction in Patients with Polycystic Ovary Syndrome. Journal of Reproductive Medicine, 60, 495-500.

为你推荐